FDA thyroid cancer warning on GLP-1 drugs is narrower than many patients think

Thyroid surgeons at the Clayman Thyroid Center say the boxed warning on semaglutide, tirzepatide and similar GLP-1 drugs applies to rare medullary thyroid cancer and MEN2, not the common thyroid cancers most patients get. New large studies have not found an increased risk of common thyroid cancers, though experts say the long-term picture is still being studied.

Why it matters: - Millions of Americans use GLP-1 receptor agonists such as semaglutide and tirzepatide. - The FDA boxed warning can prompt fear that these drugs raise the risk of all thyroid cancers. - The warning actually applies to a rare cancer subtype and a rare inherited syndrome, which changes how most patients should think about the label.

What happened: - During Thyroid Cancer Awareness Month, the Clayman Thyroid Center in Tampa, Florida, addressed questions patients are asking about the thyroid cancer warning on GLP-1 drugs. - The center said the warning is real, but far narrower than many people believe. - Gary Clayman, DMD, MD, FACS, founder and surgeon-in-chief of the Clayman Thyroid Center, said patients often assume a weight-loss drug caused a papillary thyroid cancer diagnosis or that a thyroid nodule means they must stop treatment.

The details: - The FDA boxed warning on GLP-1 receptor agonists concerns medullary thyroid carcinoma, or MTC, and multiple endocrine neoplasia type 2, or MEN2. - MTC arises from parafollicular C cells and accounts for about 3% to 4% of thyroid cancers in the United States. - About 95% to 97% of thyroid cancers are differentiated cancers, including papillary, follicular and oncocytic, or Hürthle cell, cancers. - The warning does not apply to those common forms. - The warning originated in rodent toxicology studies in which mice and rats given GLP-1 receptor agonists developed C-cell tumors. - Human thyroid C cells have substantially lower levels of GLP-1 receptors than rodent C cells, and the downstream signaling differs. - A Scandinavian cohort study in The BMJ in 2024 followed 145,410 GLP-1 receptor agonist users in Denmark, Norway and Sweden and compared them with 291,667 DPP-4 inhibitor users over a mean 3.9 years. - That study found a hazard ratio for thyroid cancer of 0.93, with a 95% confidence interval of 0.66 to 1.31. - An international multisite cohort study in Thyroid in 2025 examined 98,147 GLP-1 receptor agonist users across Canada, Denmark, Norway, South Korea, Sweden and Taiwan. - That study reported a hazard ratio of 0.81, with a 95% confidence interval of 0.59 to 1.12. - A French nested case-control analysis in Diabetes Care in 2023 reported an increased risk, with a hazard ratio of 1.58 for one to three years of cumulative use. - Later commentary and the larger cohort studies have suggested detection bias may explain much of that signal. - The studies note a limitation: follow-up has only covered a few years, so a longer-term risk cannot be ruled out yet. - GLP-1 receptor agonists are contraindicated for people with a personal or family history of medullary thyroid carcinoma and for people with MEN2. - There is no contraindication for people with prior papillary, follicular or Hürthle cell thyroid cancer. - There is no contraindication for people with common thyroid nodules. - Routine extra thyroid imaging or calcitonin testing is not indicated just because a patient takes one of these drugs.

Between the lines: - The current evidence separates a real but narrow label warning from the broader public anxiety around thyroid cancer. - The strongest human studies so far do not show an increased risk of the common thyroid cancers that account for nearly all diagnoses. - The pattern of more medical visits and more imaging among GLP-1 users may uncover nodules and cancers that were already there. - Clayman Thyroid Center says its position reflects the evidence as it stands now, not a claim that the issue is permanently settled.

What's next: - Patients should not stop a prescribed medication based on a news article. - People with a personal or family history of thyroid cancer should discuss their risk with the prescribing physician. - The Clayman Thyroid Center says questions about any long-term risk will depend on future follow-up from larger studies. - The center estimates 45,240 Americans will be diagnosed with thyroid cancer in 2026. - The center urges people to watch for a new neck lump, neck swelling, persistent neck change, difficulty swallowing or unexplained hoarseness. - More information is available at Know Your Neck and in the center's full evidence review, GLP-1 Medications and Thyroid Cancer Risk.